Table 3.
Baseline characteristics and clinical data of each PBC and control patient
| Case # | Gender | Age | Clinical presentation | AutoAbs |
|---|---|---|---|---|
| PBC 1 | F | 58 | Fatty liver | AMA+/ANA+/ASMA− |
| PBC 2 | M | 55 | Elevated LFTs | AMA+/ANA+/ASMA+ |
| PBC 3 | F | 41 | Elevated LFTs | AMA+/ANA+/ASMA− |
| PBC 4 | M | 54 | Elevated LFTs | AMA+/ANA−/ASMA− |
| PBC 5 | F | 38 | Elevated LFTs | AMA+/ANA−/ASMA− |
| PBC 6 | F | 52 | History of PBC | AMA+/ANA+/ASMA− |
| PBC 7 | F | 52 | History of PBC | AMA+/ANA−/ASMA− |
| PBC 8 | F | 26 | Elevated LFTs | AMA+/ANA+/ASMA− |
| PBC 9 | F | 64 | Elevated LFTs | AMA+/ANA+/ASMA− |
| PBC 10 | F | 51 | Fatty liver | AMA+/ANA+/ASMA− |
| PBC 11 | F | 29 | History of PBC with cirrhosis | AMA+/ANA+/ASMA− |
| PBC 12 | F | 39 | History of PBC with cirrhosis | AMA+/ANA−/ASMA− |
| PBC 13 | F | 61 | History of PBC with cirrhosis | AMA+/ANA+/ASMA− |
| PBC 14 | F | 53 | History of PBC with cirrhosis | AMA+/ANA−/ASMA− |
| Control 1 | F | 57 | Liver lesion, FNH | None evaluated |
| Control 2 | M | 37 | Elevated LFTs | AMA−/ANA−/ASMA− |
| Control 3 | F | 52 | Liver lesion, melanoma | None evaluated |
AutoAbs, autoantibodies; PBC, primary biliary cholangitis; F, female; M, male; LFTs, liver function tests; AMA, anti-mitochondrial antibodies; ANA, anti-nuclear antibodies; ASMA, anti-smooth muscle antibodies.